{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:13:29Z","timestamp":1753892009880,"version":"3.41.2"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:00:00Z","timestamp":1700092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold> Randomized, controlled trials of molnupiravir in real-world use during the Omicron wave are scarce. The frequency of hospitalization and death is low, so further research is needed to confirm the virological efficacy of molnupiravir.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> A single-center, randomized, controlled clinical trial was conducted, and 111 hospitalized coronavirus disease 2019 (COVID-19) patients were randomly assigned at a ratio of 1:1. Fifty-three patients in the molnupiravir group were administered 800\u00a0mg of molnupiravir twice daily for 5 days in addition to the standard therapy, and 58 patients in the control group only received the standard therapy in accordance with local guidelines. The antiviral effect and adverse events were evaluated during the follow-up.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> The median viral clearance time in the molnupiravir group was significantly shorter than that in the control group (<jats:italic>p<\/jats:italic> = 0.003). Furthermore, patients who started molnupiravir therapy within 3 days had significantly shorter viral clearance time than the controls (<jats:italic>p<\/jats:italic> = 0.003). In the vaccinated subgroup, molnupiravir therapy was also associated with a shorter viral clearance time (<jats:italic>p<\/jats:italic> = 0.003). A total of three adverse events, which were minor, were reported in the molnupiravir group. One of the patients had mild liver function abnormalities, and all of them were resolved without intervention. However, the remission time was similar between the two tested groups.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Molnupiravir exhibited good viral replication inhibitor efficacy in patients with Omicron variant vaccine breakthrough COVID-19 infection.<\/jats:p><jats:p><jats:bold>Clinical Trial Registration:<\/jats:bold> [<jats:ext-link>https:\/\/www.chictr.org.cn\/<\/jats:ext-link>], identifier [ChiCTR2200059796].<\/jats:p>","DOI":"10.3389\/fphar.2023.1197671","type":"journal-article","created":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T12:46:44Z","timestamp":1700138804000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of molnupiravir in patients with Omicron variant vaccine breakthrough COVID-19 infection: a randomized, controlled trial"],"prefix":"10.3389","volume":"14","author":[{"given":"Yayun","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiyong","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aijing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingling","family":"Ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingxiao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenhan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wu","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuesong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.3390\/jcm11133838","article-title":"Current effective therapeutics in management of COVID-19","volume":"11","author":"Atluri","year":"2022","journal-title":"J. Clin. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0140-6736(22)02597-1","article-title":"Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial","volume":"401","author":"Butler","year":"2023","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"eabm7621","DOI":"10.1126\/scitranslmed.abm7621","article-title":"The adenosine analog prodrug ATV006 is orally bioavailable and has preclinical efficacy against parental SARS-CoV-2 and variants","volume":"14","author":"Cao","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.cell.2021.12.046","article-title":"SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses","volume":"185","author":"Dejnirattisai","year":"2022","journal-title":"Cell"},{"key":"B5","doi-asserted-by":"publisher","first-page":"eabl7430","DOI":"10.1126\/scitranslmed.abl7430","article-title":"A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus","volume":"14","author":"Fischer","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s43440-022-00408-6","article-title":"Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance","volume":"74","author":"Flisiak","year":"2022","journal-title":"Pharmacol. Rep."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe covid-19","volume":"382","author":"Grein","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"877101","DOI":"10.3389\/fimmu.2022.877101","article-title":"SARS-CoV-2 omicron variant: epidemiological features, biological characteristics, and clinical significance","volume":"13","author":"Guo","year":"2022","journal-title":"Front. Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"103737","DOI":"10.1016\/j.amsu.2022.103737","article-title":"Understanding the omicron variant (B.1.1.529) of SARS-CoV-2: mutational impacts, concerns, and the possible solutions","volume":"78","author":"Islam","year":"2022","journal-title":"Ann. Med. Surg. (Lond)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of covid-19 in nonhospitalized patients","volume":"386","author":"Jayk Bernal","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S1473-3099(22)00644-2","article-title":"Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial","volume":"23","author":"Khoo","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1007\/s40121-022-00716-7","article-title":"Disease progression of hospitalized elderly patients with omicron BA.2 treated with molnupiravir","volume":"11","author":"Liu","year":"2022","journal-title":"Infect. Dis. Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.3390\/antibiotics11111541","article-title":"Real-life experience of molnupiravir in hospitalized patients who developed SARS-CoV2-infection: preliminary results from CORACLE registry","volume":"11","author":"Lupia","year":"2022","journal-title":"Antibiotics"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e29165","DOI":"10.1097\/MD.0000000000029165","article-title":"Omicron SARS-CoV-2 variant of concern: a review on its transmissibility, immune evasion, reinfection, and severity","volume":"101","author":"Mohsin","year":"2022","journal-title":"Med. Baltim."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.3390\/pathogens11101121","article-title":"Molnupiravir as an early treatment for COVID-19: a real life study","volume":"11","author":"Pontolillo","year":"2022","journal-title":"Pathogens"},{"key":"B16","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3892\/mmr.2022.12779","article-title":"Lessons from SARS-CoV-2 and its variants (review)","volume":"26","author":"Qin","year":"2022","journal-title":"Mol. Med. Rep."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1080\/22221751.2022.2078230","article-title":"An open, prospective cohort study of VV116 in Chinese participants infected with SARS-CoV-2 omicron variants","volume":"11","author":"Shen","year":"2022","journal-title":"Emerg. Microbes Infect."},{"key":"B18","doi-asserted-by":"publisher","first-page":"102396","DOI":"10.1016\/j.dsx.2022.102396","article-title":"An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19","volume":"16","author":"Singh","year":"2022","journal-title":"Diabetes Metab. Syndr."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.3390\/ph15091065","article-title":"Real-world use of molnupiravir in the treatment of outpatients with SARS-CoV-2 infection\u2014a patient profile based on the experience of a tertiary infectious disease center","volume":"15","author":"Streinu-Cercel","year":"2022","journal-title":"Pharmaceuticals"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1007\/s10238-022-00949-3","article-title":"Real-world clinical outcomes of treatment with molnupiravir for patients with mild-to-moderate coronavirus disease 2019 during the Omicron variant pandemic","volume":"23","author":"Suzuki","year":"2022","journal-title":"Clin. Exp. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1056\/NEJMc2119407","article-title":"Efficacy of antibodies and antiviral drugs against covid-19 omicron variant","volume":"386","author":"Takashita","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ijid.2020.11.142","article-title":"Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: a randomized, comparative, open-label, multicenter, phase 3 clinical trial","volume":"103","author":"Udwadia","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"105252","DOI":"10.1016\/j.antiviral.2022.105252","article-title":"Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern","volume":"198","author":"Vangeel","year":"2022","journal-title":"Antivir. Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/S1473-3099(22)00507-2","article-title":"Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study","volume":"22","author":"Wong","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"939573","DOI":"10.3389\/fphar.2022.939573","article-title":"Antiviral efficacy and safety of molnupiravir against omicron variant infection: a randomized controlled clinical trial","volume":"13","author":"Zou","year":"2022","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1197671\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T12:46:49Z","timestamp":1700138809000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1197671\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,16]]},"references-count":25,"alternative-id":["10.3389\/fphar.2023.1197671"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1197671","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2023,11,16]]},"article-number":"1197671"}}